Inhibrx Biosciences (INBX) Total Liabilities (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Total Liabilities for 3 consecutive years, with $138.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Liabilities rose 193.51% year-over-year to $138.5 million; the TTM figure through Dec 2025 stood at $138.5 million (up 193.51% YoY), while the FY2025 annual figure was $138.5 million, up 193.51% from the prior year.
• Total Liabilities declined to $138.5 million in Q4 2025 per INBX's latest filing, from $140.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $264.4 million in Q4 2023 and bottomed at $39.1 million in Q2 2024.
• Historically, Total Liabilities has averaged $120.7 million across 3 years, with a median of $139.6 million in 2025.
• Annual changes were most pronounced in 2024 — Total Liabilities sank 82.15% — and 2025, when it jumped 267.61%.
• Inhibrx Biosciences' Total Liabilities stood at $264.4 million in 2023, then tumbled by 82.15% to $47.2 million in 2024, then surged by 193.51% to $138.5 million in 2025.
• Business Quant data shows INBX's Total Liabilities at $138.5 million in Q4 2025, $140.6 million in Q3 2025, and $143.6 million in Q2 2025.